Literature DB >> 26333119

Enantioselective determination of (R)- and (S)-lansoprazole in human plasma by chiral liquid chromatography with mass spectrometry and its application to a stereoselective pharmacokinetic study.

Luning Sun1, Yang Cao2, Huiwen Jiao3, Yunqian Fang3, Zhicheng Yang3, Mingliang Bian1, Hongwen Zhang1, Xiaojian Gong3, Yongqing Wang1.   

Abstract

A simple and enantioselective method was developed and validated for the simultaneous determination of (R)- and (S)-lansoprazole in human plasma by chiral liquid chromatography with tandem mass spectrometry. Lansoprazole enantiomers and internal standard (esomeprazole) were extracted from plasma using acetonitrile as protein precipitating agent. Baseline chiral separation was achieved within 9.0 min on a Chiralpak IC column (150 mm × 4.6 mm, 5 μm) with the column temperature of 30°C. The mobile phase consisted of 10 mM ammonium acetate solution containing 0.05% acetic acid/acetonitrile (50:50, v/v). The mass spectrometric analysis was performed using a QTrap 5500 mass spectrometer coupled with an electrospray ionization source in positive ion mode. The multiple reactions monitoring transitions of m/z 370.1→252.1 and 346.1→198.1 were used to quantify lansoprazole enantiomers and esomeprazole, respectively. For each enantiomer, no apparent matrix effect was found, the calibration curve was linear over 5.00-3000 ng/mL, the intra- and inter-day precisions were below 10.0%, and the accuracy was -3.8 to 3.3%. Analytes were stable during the study. No chiral inversion was observed during sample storage, preparation procedure and analysis. The method was applied to the stereoselective pharmacokinetic studies in human after intravenous administration of dexlansoprazole or racemic lansoprazole.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Chiral liquid chromatography; Dexlansoprazole; Lansoprazole; Pharmacokinetics; Tandem mass spectrometry

Mesh:

Substances:

Year:  2015        PMID: 26333119     DOI: 10.1002/jssc.201500653

Source DB:  PubMed          Journal:  J Sep Sci        ISSN: 1615-9306            Impact factor:   3.645


  3 in total

1.  Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.

Authors:  Yue-Qi Li; Zheng-Yu Yan; Hong-Wen Zhang; Lu-Ning Sun; Hui-Wen Jiao; Mei-Feng Wang; Li-Yuan Yu; Lei Yu; Zi-Qing-Yun Yuan; Ling Meng; Yong-Qing Wang
Journal:  Eur J Clin Pharmacol       Date:  2017-01-31       Impact factor: 2.953

2.  Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.

Authors:  Lihua Wu; Jian Liu; Yunliang Zheng; You Zhai; Meihua Lin; Guolan Wu; Duo Lv; Jianzhong Shentu
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

3.  Impact of Gastric H+/K+-ATPase rs2733743 on the Intragastric pH-Values of Dexlansoprazole Injection in Chinese Subjects.

Authors:  Lu-Ning Sun; Yang Cao; Yue-Qi Li; Yun-Qian Fang; Hong-Wen Zhang; Mei-Feng Wang; Li-Jun Xie; Juan Chen; Zhi-Cheng Yang; Ming-Liang Bian; Hao Li; Pei-Pei Zhang; Ji-Fu Wei; Ling Meng; Xue-Hui Zhang; Ping Zhao; Yong-Qing Wang
Journal:  Front Pharmacol       Date:  2017-09-22       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.